Main description:

Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.

Contents:

Tumor Microenvironment: Immune Effector and Suppressor Imbalance

Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?

Liquid Biopsies: New Technology and Evidence

Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma:

Clinical Activity and Mechanisms of Resistance

Immune Therapy: What Can We Learn From Acquired Resistance?

Management of Brain Metastases

Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors

Therapeutic Advances in Small Cell Lung Cancer Management

Small Cell Lung Cancer: Biology Advances

Immunotherapy and Radiotherapy: New Strategies

Ultimate Precision: Targeting Cancer But Not Normal Self-Replication